A 14-year-old male presented in 1991 with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria. The patient was maintained on transfusion support until July 1998, when he received an ...

OBJECTIVE: To determine the most effective, evidence-based approach to the use of platelet transfusions in patients with cancer. OUTCOMES: Outcomes of interest included prevention of morbidity and ...

THE variability in the natural history of both acquired and idiopathic aplastic anemia makes it difficult to evaluate the success of any specific program of therapy. With careful attention to ...

Eltrombopag combined with immunosuppressive therapy in pediatric patients with severe aplastic anemia achieved a 54.9% overall response rate at 26 weeks, with a 71.4% response in relapsed/refractory ...

The US Food and Drug Administration (FDA) has approved the targeted agent ivosidenib (Tibsovo, Agios Pharmaceuticals) for adults with relapsed or refractory acute myeloid leukemia (AML) who harbor ...

GROSS bleeding is a frequent and major complication in patients with acute leukemia. The etiology of this bleeding is closely related to thrombocytopenia, 1 although other coagulation abnormalities ...

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--LightIntegra Technology (LIT), developer of the first 5-minute test for platelet activation status, announced that it has received $5.3 million USD in ...

Other than bone marrow transplantation, splenectomy is the only effective, long term therapy for the severe thrombocytopenia of Wiscott-Aldrich Syndrome (WAS). Occasional WAS patients demonstrate ...

Idhifa (enasidenib) was granted approval by the Food and Drug Administration (FDA) today, for the treatment of patients who have relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).